• Company has signed partnership with Sanmina Corp., a global contract electronics manufacturer, that sets the foundation for the commercialization and launch of products
• SOLY’s Rapid Acoustic Pulse device, designed to use shockwaves to accelerate tattoo removal, received institutional review board approval as a non-significant risk device
• Higher energy versions of acoustic pulse devices are in early stages of development for potential treatment of cellulite and other indications

Soliton Inc. (NASDAQ: SOLY) has reached an agreement with Sanmina, one of the world’s largest medical device manufacturers, to provide the design and testing to advance Soliton’s Rapid Acoustic Pulse (“RAP”) device for use in future clinical trials. The successful execution of this strategy is expected to lay the foundation for a commercial launch of Soliton’s products (http://ibn.fm/NLeYu).

RAP is a device that uses proprietary platform technology licensed from the MD Anderson Cancer Center. The device is designed to use rapid pulses of acoustic shockwaves together with existing lasers to accelerate the removal of unwanted tattoos.

Soliton also announced that its RAP device received institutional review board approval as a non-significant risk device. The FDA-registered board has been designated to review and monitor biomedical research involving human subjects. Subsequently, Soliton conducted several human clinical trials to study the use of the RAP device to accelerate tattoo fading and also initiated a proof-of-concept trial in humans for the reduction of cellulite (http://ibn.fm/iAY14).

“Working with Sanmina in this commercialization phase not only provides us with world-class quality and documentation, but we also believe it will make for a smoother transition to manufacturing, which we expect to begin here in the US later this year,” Soliton CEO Dr. Chris Capelli stated in a news release.

Based in Houston, Texas, Soliton is a medical device company with a proprietary platform technology licensed from the University of Texas on behalf of MD Anderson.

Also in the early stages of development is a device that uses higher energy versions of acoustic pulse devices for potential stand-alone treatment of cellulite and other indications. Both products by Soliton are investigational and not yet available for sale in the United States.

For more information, visit the company’s website at www.Soliton.com

• Wildflower reported 10th consecutive quarter of increased revenue
• Company included CBD products in the Four Seasons Hollywood Swag Bag for the 2019 Oscars
• Wildflower opened a branded general store in Lower Manhattan in a high-occupancy office tower housing established digital media companies

For the 10th consecutive quarter, Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF), a cannabis company focused on developing and designing branded products, has seen an increase in revenue (http://ibn.fm/XFuMA). The second quarter of 2019 brought in $1.4 million in sales, a $0.4 million increase over the previous quarter, which is representative of an increase that’s consistent across all sources.

Headquartered in Vancouver, Canada, the company markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States. WLDFF brands are currently distributed throughout the U.S., to more than 300 stores nationwide. The company plans to expand into Canada’s recreational and medicinal markets and is eyeing international locations, as well. Currently, Wildflower is focused on increasing brand recognition in the U.S. market as part of a strategic move to become a global wellness brand leader.

Wildflower CBD products were included in the Four Seasons Hollywood Swag Bag for the 2019 Oscars. This opportunity increased the company’s visibility and provided a chance to showcase an assortment of products, including the Cool Stick, a quick, convenient muscle, joint and back pain-relief treatment.

Wildflower has three brands: Wildflower Wellness, King Extracts and Exclusive. Each brand operates under the company’s unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. Together, the high quality products are helping Wildflower create a global wellness brand.

In January, the first Wildflower by Bridges General store opened in Lower Manhattan, quickly followed by a shop-in-shop concept at the Bridges General store located in the iconic Eleven Madison building. The complete line of Wildflower Wellness CBD products, along with exclusive product offerings, will be available to in-store customers. A CBD knowledge bar is also available at which customers can find information about how to incorporate CBD into a natural, plant-based regime for holistic health. The addition of Wildflower by Bridges General stores will complement the company’s already existing and thriving online and retail presence nationwide.

For more information, visit the company’s website at www.WildflowerBrands.co

• QMC Quantum Minerals focuses on developing first-rate lithium, silver, gold, nickel, copper and zinc prospects
• The company’s properties include its flagship Irgon Lithium Mine Project and two VMS properties
• QMC is set to leverage the growing global demand for lithium

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX.V: QMC) (FSE: 3LQ) is engaged in the exploration and development of a major spodumene-bearing lithium project and two volcanic massive sulphide (“VMS”) copper, lead and zinc properties. The company is at the vanguard in North America to supply lithium as demand for the white metal that is powering EVs (electronic vehicles), mobile phones and most of today’s electronic devices increases. In 2017, demand for lithium by lithium-ion battery manufacturers increased by 46 percent (http://ibn.fm/7tLJj).

The company’s flagship property is the Irgon Lithium Mine Project. The Irgon property is situated within the east-trending Mayville-Cat-Euclid Greenstone Belt (http://ibn.fm/lflJJ) located approximately 20 kilometers north of the world-class TANCO Mine. The Irgon Project consists of the Irgon Dike and a number of other known spodumene-bearing pegmatite dikes located within the Irgon property. This property consists of 22 contiguous mineral claims and encompasses 11,325 acres. The Irgon Dike previously hosted a developed lithium mine that closed in 1957 due to falling lithium prices.

Irgon has an historic (non NI 43-101 compliant) mineral estimate of 1.2 million tons grading 1.51 percent Li2O over a strike length of 365 meters (1,200 ft.) and to a depth of 213 meters (700 ft.) (http://ibn.fm/K09Ad). The dike remains open below this level. There is a three-compartment shaft on the Irgon Dike sunk to a depth of 241 feet with 1,200 feet of drifting off the 200-foot level. At present, QMC is conducting a drill program and evaluating the best approach to resume mining at this property. The company anticipates bringing historic and current data up to NI 43-101 standards subsequent to the completion of the current drill program.

There is considerable potential to rapidly increase tonnage at the Irgon Lithium Mine Project (http://ibn.fm/dD4Ol). An interactive 3D model of the Irgon Dike demonstrates that exploration and underground development have only taken place on the central portion of the dike. QMC’s focus for the Irgon Project is a 2,500-meter drill program designed by its consultant, SGS Canada, to confirm the historic lithium oxide assay results documented in the 1953-54 drill program.

QMC subsequently plans to bring the Irgon property into production. The company’s onsite geologists recently reported visual confirmation of substantial spodumene mineralization within the core samples gained from the initial phase of drilling (http://ibn.fm/4Q4zh).

With increasing demand for lithium coming from lithium-ion battery manufacturers, QMC Quantum Minerals is on course for greater growth. The company offers investors the opportunity to partake in a burgeoning market, with lithium demand anticipated to increase by 83 percent by 2027. QMC remains committed to its vision of reawakening the promise of Manitoba’s historically rich lithium properties.

In addition to the Irgon Lithium Mine Project, QMC holds title to two VMS copper-, lead- and zinc-bearing properties. These are the Rocky Lake and Rocky Namew Properties, which together are known as the Namew Lake District Project and are fully owned by QMC. This project encompasses 57,000 acres and is located in one of the world’s most productive mining regions, the Flin Flon/Snow Lake mining district in northwest Manitoba (http://ibn.fm/7vduw).

Results from QMC’s 2012 drilling program on the Namew Project confirmed massive sulphide mineralization in drill holes collared on three versatile time domain electro-magnetic targets. The company believes that the Namew Lake District Project has the potential to host several distinct VMS ore bodies and notes that the Namew Lake Project remains a hugely prospective exploration target with strong future potential (http://ibn.fm/mQjv3).

All of QMC’s properties are in Manitoba. QMC Quantum Minerals has its corporate headquarters in Vancouver, British Columbia.

For more information, visit the company’s website at www.QMCMinerals.com

• Spectrum Global Solutions maintains strong industry presence through its pursuit and strategic acquisition of choice businesses
• The company is positioned to meet the growing demand for deep fiber investments
• Spectrum Global has received $1.6 million in new contract awards, signaling an accelerated growth pattern for this year

Spectrum Global Solutions Inc. (OTCQB: SGSI), a leading single-source provider of cost-effective, scalable and robust solutions for those in the communications industry, recently announced that, over the past two weeks, it has received over $1.6 million in new contract awards to support carrier network upgrades.

In a news release (http://ibn.fm/N8dGH), CEO and President Roger Ponder stated, “These new orders show an acceleration of the growth we have predicted for this year. This growth in opportunities, when coupled with the unique solutions and technology brought to market through our pending WaveTech merger has us very excited for the future of our company.”

Upon completion of their pending merger, Spectrum Global and WaveTech Global Inc. will create a consolidated entity worth more than $130 million and plan on seeking approval for uplisting to the Nasdaq as soon as possible.

Spectrum Global owns and operates several subsidiaries, allowing it to provide comprehensive services that cover all aspects of fiber networks and infrastructure. Its subsidiary companies include AW Solutions Inc.; ADEX Corporation; Telnet Solutions Inc.; and Tropical Communications Inc. These subsidiaries enable Spectrum Global to provide comprehensive platforms and services covering all aspects of the communications industry, including development, deployment and maintenance of wireless/distributed antenna systems, wireline and fiber networks and infrastructure. With its subsidiary base diversified in many aspects of the industry, Spectrum Global has been able to create a strong industry foothold through its local, regional, national and global products, which vary in size and complexity.

The telecommunications industry is perched on the brink of tremendous growth, as it anticipates huge consumer demand for 5th generation (5G) mobile networking. This growth is predicted to be driven by increasing mobile data traffic, among other things. As more and more daily interactions are carried out on smartphones, tablets and other network-connected devices, companies like Spectrum Global are poised to take advantage of the $150 billion in fiber investment predicted to be required in the United States over the next five to seven years, as forecast by Deloitte (http://ibn.fm/b6kMQ).

For more information, visit the company’s website at www.SpectrumGlobalSolutions.com

• SinglePoint is building a cannabis-friendly portfolio through ancillary asset acquisitions fueled by an LOI to inject $12 million in capital
• The company’s acquisition agreement with brokerage Direct Solar and customer lead generator AI Live Transfers leads the way for solar power boost to portfolio
• A new interview with SinglePoint and Direct Solar highlights the companies’ enthusiasm for the potential of completing the agreement by April 15

Technology-building firm SinglePoint Inc. (OTCQB: SING) is advancing its commitment to the environment and its investment in the cannabis industry through the acquisition of two companies that have successfully applied the Lending Tree model to the solar power products and services industries. A new interview featuring SinglePoint President Wil Ralston and Direct Solar Founder Pablo Diaz highlights the companies’ expectations for the acquisition agreement involving Direct Solar and affiliate AI Live Transfers, which is scheduled to close by April 15.

“There’s only a few ways to affect climate change, and lower the carbon footprint is it,” Diaz told Ralston in the video interview (http://ibn.fm/Ji85d). “One thing that we think is going to be a great union with SinglePoint is your access to the cannabis industry. One of the highest expenses that the cannabis industry experiences is the electricity costs. Solar is a fabulous solution to high energy costs. You want to increase margins? Great place right there… It’s an untapped market. It’s ready for maturity.”

Diaz explained how he built a side interest in solar power during a commercial real estate project that contracted for solar product installation and, ultimately, brokered for solar contractors under the Direct Solar name.

“A contractor is limited in the lending options they can give to their customer base… (And) every contractor isn’t built the same from a construction knowledge perspective,” Diaz said, noting that solar energy regulation is built on a regional utility basis that can vary from place to place.

“With the knowledge that we gained as a contractor, we built the infrastructure to be able to work with multiple contractors (nationwide)… They love us because we bring them free business,” he said. “Homeowners love (our model) because we’re a free resource to them… We’re finding solutions for the homeowner, bringing them their best options and making it efficient as a process for them and the contractor also.”

The Lending Tree model refers to strategies that connect people seeking loans to a variety of loan providers nationwide so they can shop for a service that most closely suits their needs. Diaz said that the maturing solar industry is driving many growing contractors to outsource the work involved in customer acquisition because “their time spent on that is not really translating for them in higher margins.”

Direct Solar’s revenues have increased exponentially, exceeding $1.5 million during the past year, and Diaz said that the company expects to have top $350,000 for the month of February alone.

A company press release about the acquisition agreement noted that the companies expect revenues to increase dramatically during the year following closure of the acquisition and profit margins to rise significantly, which will help bolster the company’s growth. (http://ibn.fm/jJo8D). Included in the projections is a plan to draw on AI Live Transfers’ artificial intelligence platform to seek out potential customers using a progressive technological strategy that maximizes closing agents’ time (http://ibn.fm/hmMmM), a developing lead-generation project Diaz and Ralston alluded to at the end of their interview.

SinglePoint has been highly focused on the hemp market through subsidiary SingleSeed.com and is establishing a place in the CBD market supply chain as legalization in the United States opens the door to new opportunities. SinglePoint CEO Greg Lambrecht told MoneyTV recently that the company has signed a letter of intent to raise up to $12 million to help the company fund its M&A activity in the CBD space (http://ibn.fm/KuZvU).

Analysts at the Brightfield Group forecast a $22 billion market for hemp-derived CBD by 2022 (http://ibn.fm/uTSKD).

For more information, visit the company’s website at www.SinglePoint.com

• The latest acquisition announcement is in line with Kontrol Energy’s strategic plan to build a diversified portfolio of assets and carry out a sustainable growth strategy throughout 2019
• Earlier in the year, Kontrol Energy announced its acquisition of Dimax Controls’ patents and intellectual property, adding a new product to its IoT and SaaS portfolio
• Company plans to maintain an annual growth rate of over 20 percent via strategic acquisitions and organic growth measures

On March 14, 2019, Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) announced its entry into a letter of intent (LOI) to acquire a leading electrical retrofit services provider. The acquisition is yet another milestone in a strategic series of moves by Kontrol Energy for the purpose of building assets and realizing a 2019 growth strategy.

The target of the LOI is a company that has been providing the Canadian market with high quality, value-added electrical efficiency services. The yet-unnamed company has been in business for over 15 years, and it has averaged unaudited revenues of over $6.5 million and normalized EBITDA of $700,000 over the past three years.

According to an official Kontrol Energy press release (http://ibn.fm/UGOHi), the purchase price is set at C$3 million. The deal is subject to working capital adjustments, with a holdback of $300,000 for 12 months.

Prior to the latest announcement, Kontrol Energy carried out another strategic acquisition in January 2019. On January 16, Kontrol Energy announced the purchase of Dimax Controls Canada Inc.’s patents and intellectual property assets. With the purchase, Kontrol Energy also announced that it will rebrand the Dimax energy software technology as Kontrol SmartSite (http://ibn.fm/lR9gA).

Kontrol SmartSite is a building energy software product designed to assist and enhance the operation of complex HVAC systems for large multi-residential and commercial buildings. It operates as a SaaS platform that is highly scalable.

This technology joins Kontrol SmartSuite as part of the company’s expanding portfolio of IoT energy and property technologies, as Kontrol Energy CEO Paul Ghezzi noted in a news release. The addition of the Dimax Controls intellectual property and patents is expected to enable further technological developments in the future.

On January 24, Kontrol Energy provided a detailed update on its acquisition strategy for 2019 and beyond (http://ibn.fm/b1Qa2). Growth of current operations in energy retrofits and emission compliance is a primary focus. The company will strive to expand across Canada via a series of strategic acquisitions.

As per the company’s official announcement, strategic acquisitions will come alongside organic growth initiatives. The company plans to maintain annual growth rates of over 20 percent, and the primary driver of the increase is expected to be Kontrol Energy’s technology and revenue synergies across its various operating subsidiaries.

Based in Ontario, Canada, Kontrol Energy is a leader in the field of energy efficiency. The company develops IoT and SaaS technology solutions designed to reduce clients’ overall cost of energy while also bringing down greenhouse gas emissions.

For more information, visit the company’s website at www.KontrolEnergy.com

• Plan to acquire solar energy business Direct Solar and solar marketer AI Live Transfers marks SinglePoint’s entry into power conservation industry
• Solar and wind power use rising in U.S. with government incentives, conservation efforts seen as huge draw for projected $57 billion sector
• CBD-based product line continues to generate interest with launch of Phyto-Bytes pet care product

SinglePoint Inc. (OTCQB: SING), a fully reporting company with assets across multiple sectors including mobile technology, ancillary cannabis services and sustainable technologies, continues to add branches to its family tree with new acquisitions and joint-venture announcements. SinglePoint first began as a full-service mobile technology provider – which remains a mainstay of the business – but has since diversified with new opportunities in several horizontal markets, including the rapidly-evolving CBD (cannabidiol) sector and solar power systems.

A review of SinglePoint’s recent successes and intentions for the future reveals a strategy focused on capturing opportunities when they arise through an aggressive expansion strategy across a broad range of assets. Most recently, SinglePoint signed an agreement to acquire Direct Solar and AI Live Transfers – two companies utilizing the Lending Tree model to market products and services to solar power consumers (http://ibn.fm/wpsHe).

“This is a phenomenal opportunity for SinglePoint. This changes the entire financial fundamentals for the company and enables us to continue to push forward with opportunities to continue increasing shareholder value and the overall value of SinglePoint,” SinglePoint President Wil Ralston stated in a news release.

Analysts at Zion Market Research report that the global solar panel market accounted for $30.8 billion in 2016 and is expected to reach $57.3 billion by 2022, growing at a compound annual growth rate of 10.9 percent between 2017 and 2022 (http://ibn.fm/FLnNy). Increasing government initiatives to boost adoption of renewable energy alternatives for power generation are a major selling point for consumers and businesses alike, the report notes.

Solar power and wind power met nearly 9 percent of U.S. power demand in 2018, with solar generation, provided by rooftop panels and through utility scale solar farms, growing at 25 percent, according to pv magazine’s analysis of data provided by the U.S. Department of Energy’s Energy Information Administration (http://ibn.fm/NZd2q).

Pairing solar with energy-hungry cannabis operations is another huge potential market for SinglePoint as indoor growers seek to cut back on the high cost of electricity. Legal cannabis growers are taking a hard look at solar, co-generation and battery systems as ways to combat rising energy costs, as an article published by GreenTechMedia details (http://ibn.fm/ZlO6l).

SinglePoint’s SingleSeed subsidiary distributes CBD-based produced derived from hemp via its website – www.SingleSeed.com. Multiple new product listings were added to the site in 2018, including the recently launched Phyto-Bites product. This pet-friendly brand is formulated to reduce stress, pain, separation anxiety and inflammation – particularly for dogs. The company is working with manufacturer CBD Unlimited (formerly Endexx) to distribute the product online and in stores.

“We are very excited to add this to our list of products. The pet market is a tremendous opportunity and we plan to attend and use all our contacts to promote this product at every opportunity we are presented with,” SinglePoint CEO Greg Lambrecht said in a news release (http://ibn.fm/l5ldP).

For more information, visit the company’s website at www.SinglePoint.com

• New, frozen formulation of ready-to-inject Bria-IMT increases potency, simplifies logistics and is expected to reduce cost-per-dose
• BriaCell has achieved proof of concept for its lead cellular immunotherapy product, Bria-IMT, which targets advanced breast cancer
• Founder and Director Dr. Charles L. Wiseman will be a keynote speaker at the 10th Euro Breast Cancer Summit in Paris on March 21-22

Researchers at BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology-focused biotechnology company developing targeted and safe approaches for the management of cancer, are noting significant advancements in clinical trials of the company’s lead cellular immunotherapy product, Bria-IMT, targeting advanced breast cancer.

“It’s been a very, very exciting time at BriaCell. In 2018, we achieved a number of important milestones. We achieved proof of concept for our lead clinical candidate, Bria-IMT,” BriaCell president and CEO Dr. Bill Williams states in an interview with NetworkNewsWire (http://ibn.fm/jXVPN) that describes the large unmet medical needs of advanced breast cancer and the market opportunity that they present.

The American Cancer Society (“ACS”) estimates that in 2019 there will be an estimated 1,762,450 new cancer cases diagnosed, which is the equivalent of more than 4,800 new cases each day. Of these overall cases, there will be approximately 268,600 new cases of female breast cancer, accounting for 30 percent of all new cancer diagnoses in women, as the ACS detailed in its latest report on cancer statistics (http://ibn.fm/89c55).

Perhaps more alarming is a new study showing that the number of women in the U.S. living with distant metastatic breast cancer (“MBC”), the most severe form of the disease, is growing. The researchers estimated that, as of January 1, 2017, more than 150,000 women in this country were living with MBC, and that three in four of them had initially been diagnosed with an earlier stage of breast cancer. The findings appeared online in Cancer Epidemiology, Biomarkers & Prevention and is also published on the National Cancer Institute’s website (http://ibn.fm/2Tbwk).

BriaCell is focused on enhancing the lives of cancer patients who are facing limited therapeutic options. Designed by a team of scientists and clinicians, BriaCell’s proprietary whole-cell-based technology platform continues to show its impressive potential to establish a new model for treating cancer patients.

Bria-IMT activates the immune system to destroy cancer cells in a way that’s believed to be both unique and more effective than other, similar approaches. Bria-IMT has shown promise in FDA-approved clinical trials, suggesting excellent safety and efficacy in patients who match Bria-IMT at HLA types. BriaCell also recently announced the initiation of clinical use of a novel frozen formulation of Bria-IMT for on-demand shipment to clinical sites to accommodate higher patient volumes at reduced per-dose costs (http://ibn.fm/FxIYe).

“We’re going full barrel, full force into 2019,” Williams states in the NNW interview (http://ibn.fm/GYr5o). “We have ongoing discussions with multiple potential partners to form some corporate partnerships, and we’re very optimistic about those. We have preliminary efficacy data coming out on our first six patients in the KEYTRUDA combination study, and then we have multiple opportunities to present at conferences to get the word out there.”

BriaCell continues to gather new insights on completed studies as immune responses and test results are further analyzed, which includes noting “exciting information” about the company’s ongoing combination study with KEYTRUDA that will be shared at upcoming oncology conferences.

BriaCell Founder and Director Dr. Charles L. Wiseman will be a keynote speaker at the 10th Euro Breast Cancer Summit, taking place in Paris on March 21-22, 2019. The summit’s theme for 2019 is rediscovering novel approaches toward a cure for breast cancer and women’s health (http://ibn.fm/X51BO). Wiseman’s topic is aptly titled ‘Targeted Immunotherapy for Breast Cancer – Immunotherapy – Fact, myths and experience: Myth Busters: How beautiful facts can falsify ugly theories’.

For more information, visit the company’s website at www.BriaCell.com

• Kontrol Energy focuses on smart-energy solutions for North American customers
• The company is entering the cannabis sector with its energy-efficiency and emission-compliant solutions
• Kontrol Energy recently commenced trading on the OTCQB Venture Market

Based in Vaughan, Ontario, Kontrol Energy Corp. (CSE: KNR) (OTC: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector via IoT (Internet of Things), cloud and SaaS (Software as a Service) technology. The company integrates smart-energy devices, energy software and energy retrofits to help organizations benefit from energy cost savings while reducing greenhouse gas emissions. Kontrol offers its SmartMax intelligent energy technology. Recently, Kontrol Energy was named as the seventh-fastest growing start-up in Canada in 2018 by Canadian Business and Maclean’s.

The company’s specialty is the assimilation of smart-energy technologies and solutions for North American commercial and industrial property owners and operators. Kontrol is focusing on the large North American marketplace, where up to 30 percent of energy is wasted. As such, more than $50 billion is lost each year because of this waste (http://ibn.fm/Dn6KU).

Industry analysts suggest that the multitrillion-dollar energy-efficiency market offers major opportunities over the next five years. Established market segments include energy retrofits ($71.4 billion), distributed generation ($179.9 billion), energy analytics ($33.5 billion) and greenhouse gas/carbon measurement and reduction ($1.2 trillion). The benefit to its customers is that Kontrol Energy’s solutions result in immediate and real-time energy savings in the range of 25 to 30 percent. As a result, the company’s customers have more control over energy use (http://ibn.fm/6oyFF).

With a focus on providing energy-efficiency assistance, Kontrol Energy is entering the cannabis vertical sector. The goal of its cannabis solutions is to provide energy efficiency and emission-compliance solutions to licensed producers. The company has two NDAs signed for generation and emission, and it anticipates adding 5 to 10 percent to top-line revenue over the next year (http://ibn.fm/7XsaZ) via its cannabis initiatives.

Recently Kontrol Energy announced that its common shares are now trading on the OTCQB Venture Market (http://ibn.fm/wfrCE) under ticker symbol ‘KNRLF’. The OTCQB Venture Market is a U.S. trading platform operated by OTC Markets Group in New York City.

Kontrol’s common shares will continue to trade on the Canadian Securities Exchange under symbol ‘KNR’ and on the Frankfurt Stock Exchange under symbol ‘1K8’. Eligibility for the OTCQB Venture Market involves companies being current in their financial reporting. Eligible companies must also pass a minimum bid price test and undergo a yearly company verification and management certification process.

In a news release, Kontrol Energy’s chief executive officer, Paul Ghezzi, said, “Listing on the OTCQB Venture is part of a long-term strategy to introduce the company to a broader audience. We believe trading on the OTCQB will help us enhance liquidity by providing our current and future U.S. investors with a trading platform.”

Kontrol Energy offers its customers the opportunity for high ROI on their investments in efficiency measures. The company also offers ROI opportunities to investors via its strategic accretive acquisitions and cannabis infrastructure solutions. With established operations and a strong customer base, Kontrol Energy continues to execute on its vision of smarter energy as it works to improve its customers’ bottom lines.

For more information, visit the company’s website at www.KontrolEnergy.com

• Lung cancer is one of the most commonly occurring tumors in men and women, and it is the common cancer that’s most likely to result in death among all U.S. populations
• Genprex is advancing its trademarked Oncoprex immunogene therapy as a means of bolstering the body’s protein defenses against lung tumor growth
• Clinical trials for Oncoprex are evaluating ways to team it with other targeted therapies and immunotherapies to increase the overall efficacy of the therapies

The war on deadly cancers continues to advance innovative developments in the field of targeted therapies that block the growth of cancer cells by interfering with specific tumor-growing molecules (as opposed to chemotherapy, or cytotoxic therapy, which simply interferes with all rapidly dividing cells). Genprex Inc. (NASDAQ: GNPX) is at the forefront of the battle, testing its trademarked Oncoprex immunogene therapy as a means of combating lung cancers.

Lung cancer is one of the most commonly occurring cancers among all men and women in the United States, and it is the common cancer that’s most likely to result in death among men and women of all races once it occurs, although death rates have been decreasing in recent years (http://ibn.fm/MDIqa). Overall societal lifestyle changes and advances in medical technologies have made cancers more survivable than they once might have been.

Genprex continues to focus on developing new treatments for cancer as part of its mission to develop cutting-edge gene therapies to improve patient outcomes. Targeted gene therapies have resulted in a vast amount of drug research in recent years, because gene therapies are expected to be more effective than older forms of treatments and less harmful to normal cells. Targeted therapies and immunotherapies empower the body’s own natural immune defenses against tumor development, either by adding or restoring deficient proteins or by attacking “checkpoint” molecules that inhibit the body’s cancer-fighting proteins.

Drugs established through gene research have often found only temporary effectiveness, as patients develop a resistance to them. This has led to an emerging trend to combat resistance through combination therapy in which a number of different therapeutic agents and differing modes of action team up to battle resistance-conferring mutations (http://ibn.fm/TQj3F).

Genprex’s Oncoprex therapy is an example of this trend, working in combination with targeted therapies such as U.S Food and Drug Administration (FDA)-approved drugs Tarceva and Iressa and immunotherapies such as FDA-approved drugs Opdivo and Yervoy to fight non-small cell lung cancers, which account for about 85 percent of all lung cancers (http://ibn.fm/h5sI0).

“Oncoprex is synergistic with those drugs, meaning that the combination is more effective than either drug alone. We believe that by combining Oncoprex with targeted therapies and immunotherapies, we can extend the benefit of these approved lung cancer drugs into the large majority of patients who do not now benefit from them, either because the patients’ tumors do not have the molecular profiles that indicate effectiveness of those drugs, or because the patients have developed resistance to those drugs after receiving them for some period of time,” the company’s website states.

Oncoprex’s phase I and II clinical-stage trial therapies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities (http://ibn.fm/w3bUK). The company has a portfolio of 30 issued patents and two more pending, and it is also conducting pre-clinical research to help identify which patients will be most likely to benefit from its gene therapies and which additional cancer drugs will be the most synergistic with Oncoprex.

For more information, visit the company’s website at www.Genprex.com